Research Study

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study
Principal Investigator 
John Swiston


Body Locations and Systems 
Pulmonary Hypertension 
Closed for Recruitment
Study Start/End 
Feb 24, 2016 to Jan 30, 2020
Diamond Health Care Centre, Vancouver General Hospital
Mami Okada, Research Coordinator
604-875-4111 ext.69831
Email Address
Purpose of Study 

The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.


Visit for more information.


Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.